Rivaroxaban versus fondaparinux for thromboprophylaxis after endovenous laser ablation by Keo, Hong H et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Rivaroxaban versus fondaparinux for thromboprophylaxis after endovenous
laser ablation
Keo, Hong H; Baumann, Frederic; Diehm, Nicolas; Regli, Christian; Staub, Daniel
Abstract: OBJECTIVE Endovenous heat-induced thrombosis (EHIT) and deep venous thrombosis
(DVT) are well-known complications after superficial endovenous thermoablation. We investigated the
efficacy of rivaroxaban in preventing EHIT and DVT after endovenous laser ablation (EVLA). METH-
ODS We retrospectively analyzed a consecutive series of patients presenting with truncal varicosis class
C to C undergoing EVLA. After EVLA, all patients received oral rivaroxaban (10 mg) or subcutaneous
fondaparinux (2.5 mg) once daily for 3 consecutive days. The primary end point was the composite of
EHIT or DVT assessed by duplex ultrasound imaging after 1 and 4 weeks. EHIT class 1 was defined as
the thrombus extending to the saphenofemoral junction. Extension into the deep venous system with a
cross-sectional area obstruction <50% was considered EHIT class 2. EHIT class 3 was defined as >50%
cross-sectional area obstruction. EHIT class 4 was total occlusion of the femoral vein. The secondary end
points were minor or major bleeding, paresthesia, and skin burns. RESULTS Between February 2009 and
December 2015, 391 patients (473 limbs) were treated with EVLA of the truncal saphenous vein. The
primary end point occurred in 13 of 166 (7.8%) and 14 of 225 (6.2%) after 1 week and in 13 of 166 (7.8%)
and 15 of 225 (6.7%) after 4 weeks comparing the rivaroxaban and fondaparinux groups (P = .659). EHIT
class 1 was observed in 20 patients (5.1%) and EHIT class 2 in five (1.3%). No patients had EHIT class
3 or 4. The incidence of DVT was one of 166 (0.6%) in the rivaroxaban group and two of 225 (0.9%) in
the fondaparinux group (P = .750). Minor bleeding events occurred in 17 of 166 patients (10.2%) and in
20 of 225 patients (8.9%), respectively (P = .652). No major bleeding events were observed. Paresthesia
was observed in 12.5% in the rivaroxaban group and in 17.8% in the fondaparinux group. No skin burns
were observed. CONCLUSIONS Rivaroxaban offers an oral medication approach showing no difference
in preventing EHIT and DVT compared with fondaparinux, without increased bleeding risk.
DOI: https://doi.org/10.1016/j.jvsv.2017.04.017
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-151436
Journal Article
Accepted Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Keo, Hong H; Baumann, Frederic; Diehm, Nicolas; Regli, Christian; Staub, Daniel (2017). Rivaroxaban
versus fondaparinux for thromboprophylaxis after endovenous laser ablation. Journal of Vascular Surgery.
Venous and Lymphatic Disorders, 5(6):817-823.
DOI: https://doi.org/10.1016/j.jvsv.2017.04.017
2
 1 
The Effect of a New Angiographic Imaging Technology on Radiation Dose in 
Visceral Embolization Procedures  
 
 
Frederic Baumann, MD 1,2; Constantino Peña MD 1, Roman Kloeckner, MD 2, Barry T 
Katzen MD 1; Ripal Gandhi MD 1; James B Benenati MD 1 
 
1 Miami Cardiac & Vascular Institute, Baptist Hospital, Florida Miami 
2 Clinical and Interventional Angiology, University Hospital of Zurich, Zurich, 
Switzerland 
3 Interventional Radiology, University Hospital of Mainz, Germany 
 
 
Corresponding Author 
Frederic Baumann, MD 
Miami Cardiac & Vascular Institute (MCVI)  
Baptist Hospital of Miami     
8900 N. Kendall Drive      
Miami, Florida 33176 
Phone: 786-702-9945 
FAX: 786-596-2999 
E-Mail: fredericbaumann@hotmail.com 
 
   
 2 
The Effect of a New Angiographic Imaging Technology on Radiation Dose in 
Visceral Embolization Procedures  
 
 
Abstract 
 
Purpose 
To evaluate the impact of a new angiographic imaging technology on radiation dose 
during visceral embolization procedures involving both fluoroscopy and digital 
subtraction angiography. 
 
Material and Methods 
A retrospective analysis from a single-center consecutive series of patients was 
performed comparing two angiographic imaging systems. The AlluraClarity (CIQ 
[Philips Healthcare, Best, Netherlands]) was used in 100 patients (n=59 male, mean 
age: 70.6 years) from July 2013 to April 2014 and compared to the former AlluraXper 
(AX) technology used in 139 patients (n=71 male, mean age: 70.1 years) from May 
2011 to June 2013. Patients were categorized according to body-mass-index (BMI 
[kg/m2]) - group 1: BMI <25, group 2: BMI ≥25 and <30, group 3: BMI ≥30. 
Fluoroscopy time, the total dose of iodinated contrast administered and procedural 
AirKerma (Ka,r: milli Gray [mGy]) were obtained.  
 
Results 
Mean BMI was 26.4±5.0 kg/m2 in the CIQ and 26.4±7.1 kg/m2 in the AX group 
(p=.93). Fluoroscopy time and the amount of contrast media were equally distributed. 
Ka,r was 1342.9 mGy versus 2214.8 mGy (p<.001, t-test) comparing CIQ to AX. 
Comparing CIQ to AX, BMI subgroup analysis revealed a mean Ka,r of 970.1 mGy to 
1586.1 mGy (p=.003, t-test), 1484.7 mGy to 2170.1 mGy (p=.02, t-test) and 1848.8 
mGy to 3348.9 mGy (p=.001, t-test) in BMI groups 1, 2 and 3. 
 
Conclusion 
CIQ technology significantly reduced mean radiation dose by 39.4% for visceral 
embolization procedures at comparable fluoroscopy time and contrast media dose. This 
dose relationship was consistent across all BMI groups.  
 
 
Key Words 
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Introduction 
 
A significant number of patients with significant gastrointestinal bleeding can be treated 
by angiography with selective embolization of the visceral artery branches. However, 
arterial embolization of visceral arteries requires sophisticated imaging, exposing both 
operators as well as patients to high radiation dose 1. Moreover, in obese patients an 
exponential increase of ionizing radiation is required to assure proper image quality 2-4. 
In consequence, concerns have been raised on the radiation exposure of patients and 
operators, and investigations have been prompted evaluating radiation dose amounts 
and strategies for possible dose reduction 5-8.  
 
To address this major concern of radiation exposure, further developments from the 
imaging technology are required. AlluraClarity ([CIQ]; Philips Healthcare, Best, 
Netherlands) is intended to acquire equivalent image quality as the former AlluraXper 
system ([AX]; Philips Healthcare, Best, Netherlands) but for less radiation. CIQ has 
previously shown to significantly reduce radiation dose for various interventional 
cardiology-, interventional (neuro-) radiology and endovascular surgery procedures 9-16. 
Despite the challenges of comparing different imaging technologies within different 
settings, a direct comparison of CIQ and AX was performed in several studies, showing 
no significant loss of image quality 9,13,15,16. However, the CIQ technology is optimized 
for each specific acquisition protocol. Therefore, the promising results are not 
necessarily negotiable for all types of procedures and body locations. Inherently, 
achievable dose reduction for each type of procedure will be different as each requires a 
specific acquisition protocol.  
The purpose of the present study was to evaluate the potential benefit of CIQ towards 
dose reduction and its impact on the physician working habits in patients undergoing 
visceral embolization therapy, since this is a subset of procedures known to necessitate 
high radiation doses 1,2. 
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Materials and Methods 
 
Patients and Methods 
This study evaluated a consecutive series of 239 patients (CIQ: n=100 [n=59 male, 
mean age: 70.6 years], AX: n=139 [n=71 male, mean age: 70.1 years]) undergoing 
visceral embolization therapy at a tertiary referral center. The indication for visceral 
embolization was related to gastrointestinal bleeding in all patients. Information on 
patients’ demographics characteristics including weight and height (cm) and 
differentiated for CIQ and AX is provided in Table 1. Since physical conditions were 
shown to affect image acquisition and quality 2-4, body-mass-index (BMI [kg/m2]) was 
evaluated. According to the BMI values, patients were categorized into three groups: 
group 1: BMI <25 kg/m2, group 2: BMI ≥25 to <30 kg/m2 and group 3: BMI ≥30 kg/m2. 
As outlined in Table 1, there was a homogenous BMI distribution comparing the CIQ 
and AX groups. 
To estimate the benefit of the novel CIQ technology, radiation dose recordings using 
CIQ were compared to radiation dose recordings using the former AX technology 
(control group). AX measurements were obtained from May 2011 to June 2013 and 
CIQ measurements after installation in July 2013 from July 2013 until April 2014, 
respectively. All procedures were performed following the radiation safety principle of 
As Low As Reasonably Achievable for both imaging technologies. Data collection and 
analysis was performed retrospectively. In line, the interventionists were not aware that 
this data is going to be evaluated at the time of procedure. Approval from our 
institutional IRB was obtained including a waiver of informed consent due to the 
retrospective nature of the evaluation. All data were collected in a Health Insurance 
Portability and Accountability Act compliant manner.  
 
 
CIQ Technology and Measurements Obtained 
CIQ is intended to acquire the equivalent image quality as AX, but for less radiation. 
This is achieved by an improved real-time image noise reduction algorithm as well as 
hardware optimization. The algorithm utilizes real-time automatic pixel shift, motion 
compensation, temporal- and spatial noise reduction to preserve image quality, while 
associated hardware reconfiguration is intended to reduce the entrance dose by adjusting 
and optimizing the full acquisition chain for different anatomic regions 9.  
For the purpose of comparing the performance of the former AX with the novel CIQ 
technology, information on fluoroscopy time (minutes), total dose of iodinated contrast 
and AirKerma (Ka,r [milli Gray: mGy]) were evaluated. The Ka,r was calculated for the 
patient entrance reference point, which was considered the approximation of the 
patient’s skin, located in the central X-ray beam and 15 cm from the isocenter towards 
the focal spot 17. Fluoroscopy time and contrast usage served as indirect parameters for 
image quality. Similar amounts of contrast and fluoroscopy time were considered to 
indicate equivalent image quality comparing AX and CIQ. However, no direct 
comparison of image quality was performed.  
 
 
Statistical Analysis 
Categorical variables are presented as number and percentage and are compared using 
the Fisher’s exact test. Continuous variables are presented as means ± standard 
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deviation (±SD) and 95% confidence interval (CI) where appropriate, and are compared 
using an independent t-test after checking for homogeneous distribution. This was done 
for the comparison of the total study and control groups, as well as for BMI subgroup 
analysis. A p-value <0.05 was considered statistically significant. Statistical calculations 
were performed using STATA software (STATA Statistics version 14.0, StataCorp, 
College Station, Texas).  
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Results 
 
A total of 239 patients were undergoing visceral embolization procedures. As outlined 
in Table 1, patients did not differ by age, gender distribution and BMI when comparing 
the CIQ and AX cohorts. Procedural details are listed in Table 2 showing longer 
procedure times in CIQ patients (108.3±45.3 min versus 91.4±44.0 min, p=0.004, t-
test). Figure 1 illustrates BMI subgroup analysis showing a difference in the BMI group 
2 (117.0±7.1 min versus 86.8±5.0 min, p<0.001, t-test).  
Fluoroscopy time (24.7±15.9 min versus 24.8±27.3 min, p=.96, t-test) and the use of 
contrast media volume (137.9±60.2 versus 141.4±62.1, p=.67, t-test) were similar when 
comparing the CIQ and AX groups and showing no significant differences in BMI 
subgroup analysis. 
The overall Ka,r was lower in the CIQ group compared to the AX group: 
1342.9±1080.1 mGy (95%-CI: 1128.6 to 1557.2) versus 2214.8±1826.8 (95%-CI: 
1908.4 to 2421.2, p<.001, t-test).  
Accordingly, mean Ka,r was 970.1±847.2 mGy (95%-CI: 702.7 to 1237.5) versus 
1586.1±1335.0 mGy (95%-CI: 1241.2 to 1930.9) comparing CIQ versus AX (p=.003, t-
test) in BMI group 1, 1484.7±1160.6 mGy (95%-CI: 1113.5 to 1855.9) versus 
2170.1±1458.2 mGy (95%-CI: 1726.7 to 2613.4) in BMI group 2 (p=.02, t-test) and 
1848.8±1128.0 mGy (95%-CI: 1305.1 to 2392.5) versus 3348.9±2395.7 mGy (95%-CI: 
2526.0 to 4171.9) in BMI group 3 (p=.001, t-test), respectively (Figure 2).  
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Discussion 
 
There has been a rapid growth of endovascular therapies necessitating radiation within 
the last decades 18,19. In line, operators have been faced with continued exposure and 
increasing cumulative radiation dose exposure 18,19. This development and its 
consequences are a major concern not only for patients but also for the operators 
involved in angiographic interventional settings 5,7,8,20,21. As a result, efforts to 
effectively reduce radiation dose while maintaining the necessary level of image quality 
have become paramount 22. However, specific procedures such as visceral interventions 
as well as patients with higher body weight and BMI require more radiation to maintain 
image quality 2. Therefore, technical advancements are necessitated to reduce radiation 
for these patients and procedures. The present study showed an average dose reduction 
of 39.4% in patients treated with CIQ when compared to AX imaging technology and 
this finding held true for all BMI groups.  
 
Despite the challenges of comparing different imaging technologies within different 
settings, CIQ was previously shown to reduce radiation dose for no significant loss of 
image quality when compared to AX 9,10,15,16. However, Soderman et al. were the only 
one performing a 1:1 direct comparison of the image quality in an interventional 
neuroradiology setting 9. In each patient imaging was obtained using the CIQ and AX 
technologies. The images were reviewed in a randomized and blinded manner by three 
neuroradiologists and thereby, no loss of image quality was observed but the CIQ 
images were acquired using 25% of the AX radiation dose, only.   
Thereafter, multiple single center series evaluated the potential of CIQ in reducing 
radiation dose for various types of procedures. Overall, a radiation dose reduction of 
>40% was achieved in all 10-13,15,16. However, there was a wide range of radiation dose 
reduction indicating that the benefit of CIQ varies according to the procedure type and 
patients’ habitus. 
In order to properly generalize and to compare both imaging technologies in this study, 
the assessment of fluoroscopy time and the amount of contrast media utilized served as 
indirect parameters to assess procedural complexity between the two groups. The 
relatively large number of patients in both groups is also important to help compare the 
groups. Fluoroscopy time and the amount of contrast media used were similar in both 
groups (Table 2). Therefore, we suggest that the procedural complexity was comparable 
as indicated by the fluoroscopy time and the amount of contrast used, which we account 
as objective parameters.  
 
 
The present study has several limitations. First, the current analysis is based on a 
retrospective evaluation of a de-identified dataset. Therefore, it was not possible to 
review specific procedural protocols and angiograms. Nevertheless, the heterogeneous 
patient population and procedural complexity in this large study population allows for 
indirect comparison of the two imaging modalities. In addition, it was not possible to 
systematically compare the image quality of CIQ and AX technology.  
Second, there were a variety of different visceral embolization procedures included 
within the present study limiting the interpretation of procedure time and radiation dose.  
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Conclusion  
 
The present study demonstrated that radiation dose can be significantly reduced in 
patients undergoing visceral embolization procedures by the use of CIQ. As expected, 
the results show an increase in radiation dose correlating with patient size. Despite the 
variability of procedure complexity, a consistent dose reduction was identified across 
the range of patient BMI. The need to understand the amount of radiation dose 
reduction possible with new technological advances is important as we attempt to 
determine which changes are truly significant while maintaining image and procedural 
quality. Further study of these technological advances is warranted especially for 
different acquisition protocols as the number and complexity of angiographic 
interventional procedures continue to increase.   
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Legends of Figures 
 
Figure 1 
Depiction of procedure and fluoroscopy times according to BMI categories. 
 
Figure 2 
Ka,r values for the three different BMI groups. 
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Table 1 
Patients´ characteristics and demographics of 239 patients undergoing visceral 
embolization 
 AX 
n=139 
CIQ 
n=100 
p-Value 
Male, n (%) 71 (51.1) 59 (59.0) .24 
Age [years], mean (±SD) 70.1 (±16.3) 70.6 (±13.8) .80 
BMI [kg/m2], mean (±SD) 26.4 (±7.1) 26.4 (±5.0) .93 
BMI group 1, n (%) 60 (43.2) 41 (41.0) .79 
BMI group 2, n (%) 44 (31.6) 40 (40.0) .22 
BMI group 3, n (%) 35 (25.2) 19 (19.0) .28 
AX: AlluraXper, CIQ: AlluraClarity, n: number, SD: standard deviation, kg: 
kilogramm, m: meter 
BMI group 1: BMI <25 kg/m2, BMI group 2: BMI ≥25 kg/m2 and <30 kg/m2, BMI 
group 3: BMI ≥30 kg/m2  
 
 
 
  
 13 
Table 2 
Procedural details of 239 patients undergoing visceral embolization. 
 AX 
n=139 
CIQ 
n=100 
p-Value 
Procedure time [min], mean (±SD) 91.4 (±44.0) 108.3 (±45.3) .004 
Flouro time [min], mean (±SD) 24.8 (±27.3) 24.7 (±15.9) .96 
Contrast [cc], mean (±SD) 141.4 (±62.1) 137.9 (±60.2) .67 
Air Kerma [mGy], mean (±SD) 2214.8 (±1826.8) 1342.9 (±1080.2) <.001 
Air Kerma [mGy] PFM [min], mean (±SD) 103.2 (±65.6) 61.8 (±50.0) <.001 
AX: AlluraXper, CIQ: AlluraClarity, n: number, min: minutes, SD: standard deviation, 
cc: centiliter, mGy: mili Gray, PFM: per flouroscopic minute 
    
